JP2008535798A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535798A5
JP2008535798A5 JP2008500972A JP2008500972A JP2008535798A5 JP 2008535798 A5 JP2008535798 A5 JP 2008535798A5 JP 2008500972 A JP2008500972 A JP 2008500972A JP 2008500972 A JP2008500972 A JP 2008500972A JP 2008535798 A5 JP2008535798 A5 JP 2008535798A5
Authority
JP
Japan
Prior art keywords
hematocrit
dose
weekly
hemoglobin
visit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008500972A
Other languages
English (en)
Japanese (ja)
Other versions
JP5737826B2 (ja
JP2008535798A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/008620 external-priority patent/WO2006099154A1/en
Publication of JP2008535798A publication Critical patent/JP2008535798A/ja
Publication of JP2008535798A5 publication Critical patent/JP2008535798A5/ja
Application granted granted Critical
Publication of JP5737826B2 publication Critical patent/JP5737826B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008500972A 2005-03-11 2006-03-10 Vegfの阻害による貧血の処置 Expired - Fee Related JP5737826B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66063805P 2005-03-11 2005-03-11
US60/660,638 2005-03-11
PCT/US2006/008620 WO2006099154A1 (en) 2005-03-11 2006-03-10 Treating anemia by inhibition of vegf

Publications (3)

Publication Number Publication Date
JP2008535798A JP2008535798A (ja) 2008-09-04
JP2008535798A5 true JP2008535798A5 (enExample) 2012-11-01
JP5737826B2 JP5737826B2 (ja) 2015-06-17

Family

ID=36676448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008500972A Expired - Fee Related JP5737826B2 (ja) 2005-03-11 2006-03-10 Vegfの阻害による貧血の処置

Country Status (6)

Country Link
US (1) US7351411B2 (enExample)
EP (1) EP1855708A1 (enExample)
JP (1) JP5737826B2 (enExample)
AU (1) AU2006223314A1 (enExample)
CA (1) CA2598452A1 (enExample)
WO (1) WO2006099154A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) * 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
EP2724739B1 (en) 2009-07-30 2015-07-01 Tandem Diabetes Care, Inc. Portable infusion pump system
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
MY199344A (en) 2013-02-18 2023-10-24 Vegenics Pty Ltd Ligand binding molecules and uses thereof
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016008975A1 (en) 2014-07-18 2016-01-21 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
CN108697792A (zh) * 2015-11-19 2018-10-23 珠海泰瑞尚生物医药科技有限公司 用于结合vegf的方法和组合物
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
KR101685532B1 (ko) 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗pd-l1およびil-2サイトカイン
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2019173767A1 (en) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
KR102426802B1 (ko) * 2019-12-23 2022-07-28 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질을 포함하는 신생혈관형성 관련 질환의 예방 및 치료를 위한 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
IL145941A (en) 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
AUPQ592100A0 (en) 2000-02-29 2000-03-23 Council Of The Queensland Institute Of Medical Research, The A method of treatment and prophylaxis
US20050112061A1 (en) 2003-08-06 2005-05-26 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy

Similar Documents

Publication Publication Date Title
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
JP2010285439A5 (enExample)
JP2005518433A5 (enExample)
USD639321S1 (en) Rotary actuator
IL190227A (en) Phenyl derivatives - [1,2,4] - oxadiazole - 5 - On with a phenyl group, their use in medicine, pharmaceuticals containing them, and a process for preparing the pharmaceutical preparations
WO2006050250A3 (en) Dose forms comprising vx-950 and their dosage regimen
WO2008012553A3 (en) Rake with pre-filter
IL228904A0 (en) Use of milankiperan, or a suitable pharmaceutical salt, in the preparation of a drug for the treatment of fibromyalgia
IL207038A (en) History of Diazaspiro [5.5] Undecan, Pharmaceuticals Containing them, and their use in the preparation of drugs for the treatment or reduction of the risk of disease or inflammatory condition
CL2007003444A1 (es) Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
ITTO20050525A1 (it) Lembi perfezionati per ridurre gli effetti dannosi dei detriti.
WO2007092496A3 (en) 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
CL2007002376A1 (es) Compuestos derivados de pirrol sustituido; proceso de preparacion; composicion farmaceutica; y uso en enfermedades bacterianas.
IL201730A (en) History 1h - Benzaimidazole – 2 – Il – Profile – Methyl – Amino – Ethyl – 5 – Aryl – Bicyclo [2.2.2] Oct – 5 – Ann – 2 – All, Pharmaceutical preparations containing them and their use in the preparation of drugs
WO2010005565A3 (en) Method of treating glycogen storage disease
CY1110620T1 (el) Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας
WO2006047631A3 (en) Anti-mitotic anti-proliferative compounds
TWI315305B (en) Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof
WO2007143548A3 (en) Myxoma virus mutants for cancer treatment
WO2006133194A3 (en) Methods for treating viral infection with oral or injectible drug solution
WO2007116297A3 (en) Use of aminapthone for the preparation of a medicament for treating arteriophaties
WO2006078713A3 (en) Methotrexate combinations for treating inflammatory diseases